Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-12 mRNA lipid nanoparticle
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral, Intravenous
01
Overview
Interleukin-12 (IL-12) mRNA lipid nanoparticle (LNP) therapy is an immunotherapy approach designed to deliver the genetic instructions for the proinflammatory cytokine IL-12 directly into cells. IL-12 is a heterodimeric cytokine (composed of p35 and p40 subunits) that coordinates innate and adaptive immune responses by activating natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), and promoting the differentiation of naive T cells into Th1 cells. Because systemic administration of recombinant IL-12 protein has historically been limited by severe toxicity, mRNA-LNP technology allows for localized production (often via intratumoral injection) or controlled expression of the cytokine. This strategy aims to stimulate a robust anti-tumor immune response and overcome the immunosuppressive tumor microenvironment. Key clinical candidates in this space include MEDI1191 (developed by AstraZeneca and Moderna) and BNT153 (developed by BioNTech).
- Other names
- IL-12 mRNA LNPIL12 mRNA LNPIL 12 mRNA LNPmRNA-encoded IL-12
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on interleukin-12 mRNA lipid nanoparticle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-12 mRNA lipid nanoparticle.